air+djibouti

Industrials ETF 'XLI': Potential Catalyst for Growth and Expansion

Select Sector SPDR

The industrial sector, traditionally the backbone of any robust economy, is currently experiencing a resurgence. As a nation, we are focusing on revitalizing our infrastructure, which includes railroads, aviation, and heavy machinery. This renewed focus has increased demand for industrial space and sparked job creation in these sectors. An exchange-traded fund (ETF) such as the Industrials Select Sector SPDR Fund (XLI) provides investors with an efficient, cost-effective* way to gain exposure to this expanding sector. XLI offers access to key sub-sectors of the US economy which may fuel this growth. The XLI tracks a market cap-weighted index of industrial-sector stocks drawn from the S&P 500. Currently holding over $15 billion in assets under management, it has a low annual expense ratio of 0.10%, making it one of the most efficient and tradable ways to gain access to the industrial sector. The top 10 holdings** for XLI are: Caterpillar Inc. (4.28%) Union Pacific Corp. (4.25%) Boeing Co. (4.20%) General Electric Co. (3.94%) Honeywell International Inc. (3.92%) Uber Technologies (3.59%) RTX (3.43%) United Parcel Service, Inc. Class B (3.22%) Deere & Co. (3.04%) Lockheed Martin Corp. (2.84%) Dominant Market Players Caterpillar Inc., Union Pacific Corp., Boeing Co., General Electric Co., Honeywell International Inc., and Uber Technologies dominate the sector by market capitalization, representing industries such as aerospace and defense, building products, construction and engineering, electrical equipment, conglomerates, machinery, commercial services and supplies, air freight and logistics, airlines, marine, road, and rail. Investors ranging from institutional, broker-dealers, financial advisors, and retail are adding diversification to their portfolios with XLI. This actively traded ETF can be an attractive option for investors and traders seeking exposure to the sector. The foundation of any strong economy lies in the manufacturing and distribution of goods to businesses and consumers. XLI provides investors with exposure to this fundamental process that is essential to the daily operations of commerce, retail, and services. The Role of XLI in Portfolio Diversification A key aspect of building a portfolio is understanding the significance of each of the core 11 sectors of the S&P 500. The industrial sector, represented by XLI, can serve as a viable starting point for investors of all sizes seeking diversified investments. As we move forward, XLI can open doors to manufacturing and transportation, serving as a gateway to the infrastructure revitalization and industrial expansion that is currently driving our economy. DISCLAIMER: This is a work of research and should not be taken as investment or financial advice. Therefore, Select Sector SPDRs or the publisher is not liable for any decision made based on the publication. About the Company: Select Sector SPDR ETFs offer flexibility and customization opportunities. Many investors have similar outlooks, but no two are exactly alike. Select Sector SPDR ETFs let investors select the sectors that best meet their investment goals. *Ordinary brokerage fees apply **Holdings, Weightings & Assets as of 12/31/23 subject to change DISCLOSURES The S&P 500 Index is an unmanaged index of 500 common stocks that is generally considered representative of the U.S. stock market. The index is heavily weighted toward stocks with large market capitalizations and represents approximately two-thirds of the total market value of all domestic common stocks. The S&P 500 Index figures do not reflect any fees, expenses or taxes. An investor should consider investment objectives, risks, fees and expenses before investing. One may not invest directly in an index. Transparent ETFs provide daily disclosure of portfolio holdings and weightings All ETFs are subject to risk, including loss of principal. Sector ETF products are also subject to sector risk and nondiversification risk, which generally will result in greater price fluctuations than the overall market. Diversification does not eliminate risk. An investor should consider investment objectives, risks, charges and expenses carefully before investing. To obtain a prospectus, which contains this and other information, call 1-866-SECTOR-ETF (732-8673) or visit www.sectorspdrs.com. Read the prospectus carefully before investing. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is distributor for the Select Sector SPDR Trust. Media Contact: Company: Select Sector SPDRs Contact: Dan Dolan* Address: 1290 Broadway, Suite 1000, Denver, CO 80203 Country: United States Email: dan.dolan@sectorspdrs.com Website: https://www.sectorspdrs.com/ *Dan Dolan is a Registered Representative of ALPS Portfolio Solutions Distributor, Inc. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is the distributor for the Select Sector SPDR Trust. SEL007228 EXP 3/31/24 Contact Details Dan Dolan +1 203-935-8103 dan.dolan@sectorspdrs.com Company Website https://www.sectorspdrs.com/

February 02, 2024 05:00 AM Eastern Standard Time

Amesite Inc. In 2024: Growth, Partnership Building And Scaling A Zero Setup Cost AI-Driven Platform

Benzinga

By Faith Ashmore, Benzinga AI is rapidly gaining momentum and transforming industries across the board, even those that have traditionally been slow to adopt new technologies, like academia. As states increasingly recognize the need to build highly skilled workforces, community and regional colleges and universities in the U.S. are playing a more vital role than ever before. To accomplish their missions, these institutions often require more advanced software and services that can facilitate large-scale workforce development quickly and efficiently. AI-powered solutions are proving to be increasingly useful in achieving operational efficiency and meeting the needs of the future. However, not every university and college has the resources or knowledge to fully invest in AI technology. Amesite Inc. (NASDAQ: AMST) is an artificial intelligence software company that offers a cloud-based learning platform for businesses and education. The company's smart and intuitive learning environments assist organizations – including businesses, community colleges, universities, non-profits and government agencies – to launch branded learning programs easily and affordably. With a focus on providing innovative solutions, Amesite enables organizations to evolve with the times by offering a zero-cost set-up fee platform that leverages AI and facilitates personalized, engaging and efficient learning experiences. The company is known for its best-in-class learning management system (LMS) which can integrate with thousands of Application Programming Interface (APIs), enabling them to share information with different software applications. The past year saw the strategic evolution of Amesite’s business strategy to better serve its partners by moving to a much more affordable business plan with a no-cost set-up fee model, which is a key differentiator from other SaaS e-learning platforms. This change was made economically possible by the company’s implementation of its AI capabilities. The no-cost set-up fee approach significantly expands the target market for Amesite and enables companies and universities to provide professional training without big upfront investments and offer degrees and certifications to students with lower tuition fees than the competition. From an internal standpoint, Amesite says prioritizing AI-first processes and workflows has had an impact of reducing operating expenses by 51.9%. The company also reports that sales-qualified leads have seen a nearly 200% increase from the first quarter of 2023 to the first quarter of 2024. Before AI took off and was widely adopted, Amesite reports it was already engaging with and adopting the technology as one of the first ed-tech companies to embrace AI. Amesite reports it has gained momentum when compared to competitors and is now able to provide a cost-efficient product to its customers through a no-cost set-up fee model – effectively making it risk-free. Although from another industry, this is a similar approach to how Tesla (NASDAQ: TSLA) approached its EV business model and took a mass-market approach. Tesla created a standard in the auto industry that enabled it to bring on more customers, and Amesite similarly aims to set a standard in its educational industry utilizing AI in the background. Over the course of 2023, Amesite made strides in both the private and public sectors, which cumulated into the no-cost set-up fee model which has increased sales inquiries. In March, Amesite announced that it was COPPA and FERPA -compliant; these designations protect children’s safety and personal data online. This certification allows Amesite’s customers to sell learning products to over 49.5 million K12 students. The company reports that it has already seen success with the continued education market. In June, the company announced that company had received an award from the National Association for Business Resources: Michigan’s Best & Brightest in Wellness® for the fifth consecutive year. The company also announced 12 new courses with its partner, Michigan Works! Southeast (MWSE) during the year. These courses focused on how digitalization is reshaping the workplace, providing Michigan residents with valuable resources to excel in the modern workplace. In August, Amesite announced the renewal of its partnership with Central Michigan University. While there are other companies in the ed-tech space like Coursera (NYSE: COUR) and 2U (NASDAQ: TWOU), Amesite’s early AI adoption and continued evolution are beginning to result in more potential sales activity for the company in addition to achieving its no-cost set-up fee milestone but (significantly for investors) this shift began to roll out in September 2023, with an understandable delay in contract announcement wins. The company now boasts of being able to provide custom-branded, enterprise-scale systems for clients within 24 hours – and partners seem to be taking notice. Since the official rollout in September, the company announced a five-year partnership with Drake State Community and Technical College in November. Amesite also announced a five-year partnership with West Virginia Northern Community College in December. Amesite’s commitment to providing companies and organizations with the tools needed to leverage powerful AI at a low cost and with scalable options sets it apart from its contemporaries and its competition. Speaking on the commercial demand for Amesite’s tools, CEO and Founder Dr. Ann Marie Sastry shared, “Workforce development agencies have a significant opportunity to leverage modern tools to assist individuals in their growth and readiness for the job market, and we are excited to be able to provide critical skills to a multi-billion-dollar market and expect these offerings to be in high demand. At Amesite, we've focused on creating solutions that easily integrate into existing systems. Our partnership with Microsoft enables us to deploy these tools swiftly, often within a 24-hour window.” According to Market Research Future, the global AI in education market is projected to grow from $3.45 billion in 2023 to $23.82 billion in 2030. The SaaS market is expected to grow from $167 billion in 2022 to $462 billion by 2028. As Amesite’s progress indicates, companies that capitalize on these two industries and drive growth forward could have a positive outlook in the coming years. As Amesite begins to see the positive results of its new AI-enable model, investors may see that Amesite could potentially be well-positioned to continue to grow and expand its partnerships, resulting in more clients and more revenues. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

February 01, 2024 09:10 AM Eastern Standard Time

World’s largest radiology AI marketplace CARPL raises $6m to accelerate the adoption of AI in clinical workflows

CARPL

As people live longer and as emphasis on early detection of disease increases, there is a mounting burden on the healthcare services industry globally. This is being especially felt in radiology teams who are witnessing an acute shortage of radiologists. Currently, there are over 200 companies building applications using AI to automate parts of the radiologists’ work to bridge this talent gap. Today CARPL, an enterprise imaging AI marketplace platform, is announcing a $6m funding round to enable healthcare providers to access, assess and integrate these radiology AI applications into their clinical workflows through a single user-interface, single data channel and single procurement system. The seed funding round was led by Stellaris Venture Partners, a leading enterprise software investor, with participation from strategic angel investors* from Novo Holdings, Leapfrog PE, Bain & Co, Boston Consulting Group, UnitedHealth Group among others. CARPL will use the fresh funds to expand the team in North America and continue to build its tech stack. With more than 700 US-FDA approved AI applications, healthcare providers grapple with navigating the complex landscape of niche AI solutions. The daunting task involves determining the best AI solution for them and their patients, then seamlessly integrating it in the radiologists' workflows. This complexity has resulted in the sluggish pace of AI adoption in healthcare. A recent joint statement by the world’s top radiology associations also brings to light the importance of validation, deployment and monitoring of AI while being used in clinical practice. CARPL’s technology platform addresses this need using its proprietary DEV-D framework allowing healthcare providers to first Discover (D), Explore (E) and Validate (V) AI applications from CARPL’s AI marketplace, and subsequently Deploy (D) the most appropriate application across their clinical workflows. CARPL stands out as the only platform in the market with deep AI validation and monitoring capabilities, thereby ensuring safe and seamless AI deployment while upholding patient-centricity at its core. Additionally, CARPL’s universal AI viewer serves as a single user interface for radiologists, enabling them to accept, reject or refine AI outputs, which can subsequently be used to improve the performance of the AI itself. Operational since 2021, CARPL was founded by Vidur Mahajan, a physician with an MBA from the Wharton School of Business who has spent more than 12 years in the diagnostics industry. CARPL’s leadership comprises Dr Vasanth Venugopal as Chief Medical Officer, Rohit Takhar as CTO and most recently Dhruv Sahai as COO. CARPL has also ramped up its advisory team with the appointment of Dr Vijay Rao, SVP of Enterprise Imaging at Jefferson Health and a past-President of the Radiology Society of North America. “Over the past two years, we have onboarded more than 50 AI developers having 100+ AI applications, which made us the largest AI marketplace in terms of number of AI applications offered to customers. We are proud that some of the largest healthcare enterprises in the world have vetted our technology and trust us to be their partner in their AI and automation journeys.” said Dr Vidur Mahajan, CEO of CARPL. Drawing parallels with the lab medicine industry, Vidur Mahajan added: “We are democratizing radiology in the same way that automation and robotics revolutionized lab medicine, where a single pathologist signs out thousands of tests each day. We envision a future where CARPL creates ‘super-radiologists’ - AI-enabled radiologists who are ten times more productive than traditional radiologists.” Vidur Mahajan brings deep domain expertise having previously grown revenue 10x to $20m in 10 years at his family business Mahajan Imaging, a leading radiology service provider. He conceptualized CARPL under the guidance of his father Dr Harsh Mahajan, a pioneer in radiology, while working on validation and deployment of AI at Mahajan Imaging. CARPL comprises a multidisciplinary team with clinicians, scientists, engineers and business experts, all working towards the singular goal of driving exponential health outcomes using the encapsulated value of the entire AI ecosystem with the ultimate aim of ensuring access of quality diagnostics to patients. CARPL has more than 120 papers and conference presentations to its credit, and has coined some seminal concepts in clinical AI such as algorithmic audits, clinical explainability failure and unboxing AI. CARPL’s technology platform is used by the world’s top healthcare organizations like the Singapore Government, Massachusetts General Hospital (Boston), Radiology Partners (Los Angeles), University Hospitals (Cleveland), I-MED Radiology (Australia), Albert Einstein Hospital (São Paulo), Clinton Health Access Initiative, to name a few. CARPL is also creating impact in the public health space by working with the Government of India to enable large scale Tuberculosis Screening Programmes in the most remote regions of the country. As the global disease burden increases, owing to aging populations, early detection of disease and an increase in chronic/lifestyle diseases, the need for radiology services will increase, which increases the need for AI-assistance and automation in the delivery of these services. The global healthcare AI market is expected to cross $170 billion by 2029, of which almost $20 billion will be in the domain of radiology. Today, of the about 700 AI-based applications which are approved by the US-FDA, 80% are related to radiology. This number is expected to grow exponentially as access to training data and computation power becomes cheaper and easier to access. Alok Goyal, Partner at Stellaris Venture Partners commented: “The volume of imaging scans show a steady 9% year-on-year growth, outpacing the growth in the number of radiologists at a mere 1.8%. Bridging this demand gap is a crucial challenge for healthcare providers, and we believe AI will be the key. CARPL's integrated platform, designed for testing, deploying, and monitoring radiology AI applications, is poised to empower healthcare providers by seamlessly integrating AI into their clinical workflows. We are thrilled to join forces with Vidur and his team on this transformative journey.” As it becomes easier to build AI, the number and nature of AI applications used by doctors to deliver healthcare will increase exponentially. A platform approach that builds on connecting these AI developers to healthcare providers is the only way to exponentially improve the access, affordability and quality of care delivered today. CARPL is a new layer in the healthcare CIO’s stack that enables seamless access to the entire AI and analytics ecosystem through a single integrated platform. About CARPL CARPL is democratizing access to high quality healthcare by connecting AI applications and healthcare providers, exponentially improving the access, affordability and quality of medical care. CARPL enterprise imaging AI platform provides a single user-interface, data channel and procurement system for healthcare providers to access, assess, integrate and buy radiology AI applications in a safe and seamless manner. CARPL was incubated at Mahajan Imaging & Labs, India’s largest radiology service provider, as its technology division focused on building scalable clinical tools for AI validation, deployment and monitoring, under the guidance of Dr Harsh Mahajan, a pioneer in the field of radiology. For more information please visit https://carpl.ai About Stellaris Venture Partners Stellaris is an early-stage tech-focused VC firm that partners with fearless founders who dream big, think differently, and have an unstoppable desire to challenge the status quo. The fund works with these teams at nascent stages to help transform their ideas into resilient businesses. Stellaris does so with a team of seasoned, diverse operators and entrepreneurs who bring significant experience in building businesses and by providing access to some of the most successful founders and professionals. Since its inception in 2017, Stellaris has backed many market leaders such as Mamaearth, Whatfix, Propelld, Turno, Rigi, and others. For more information on Stellaris Venture Partners, visit https://www.stellarisvp.com Contact Details CARPL Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://carpl.ai/

February 01, 2024 09:00 AM Eastern Standard Time

Image

The Best AI Girl Generator Apps You Must Try 2024

Summit Ventures BV

In today's technologically driven world, AI girl generator apps have gained immense popularity for their ability to create virtual AI companions. With a plethora of options available, we've curated a list of top-notch AI girl generator tools that you should explore in 2024. These applications offer innovative AI girl generation capabilities, providing unique and engaging experiences. Table of Featured AI Girl Generators 1. Introduction to AI Generated Girls 2. Featured AI Girl Generator Tools 2.1 GPTGirlfriend.online 2.2 GlamGirls.ai 2.3 ChaiApp.pro 2.4 AI-Girlfriend.co 2.5 AI-Companion.co 3. Frequently Asked Questions 4. Conclusion Top Five AI Girl Generator Apps The world of AI girl generators has seen significant growth, offering a variety of engaging options. While each application brings its unique features to the table, GPTGirlfriend.online stands out with its exceptionally engaging interactions and a wide range of capabilities. Girlfriend GPT: Your Gateway to AI Generated Girls Girlfriend GPT is an innovative AI-powered tool that brings your favorite AI girl characters to life, offering interactive experiences. This platform provides a wide array of activities, enabling you to create a virtual space for engaging conversations with your AI girl companion. Moreover, GPTGirlfriend.online offers unrestricted content for a diverse experience. Key Features: Empowers you to create your personalized AI girl companion. Allows unrestricted interactions and conversations. Offers affordable premium and deluxe subscription plans. Resumes conversations with long-term memory. Glam Girls AI: Generate your AI Girl in Seconds Glam Girls is renowned for having the best AI generated girls in the space. This platform is designed for those interested in crafting glamorous AI characters. Whether you're looking for AI girls with a sense of style or unique personalities, GlamGirls.ai has you covered. Key Features: Multiple scenarios for AI girl generation. Customizable interface to align with your preferences. Accommodates various interests and preferences in AI girl characters. Chai App: Create AI Girls for NSFW AI Images Chai App offers an intuitive platform for generating AI girls and companions, particularly suited for NSFW AI image generation. This application excels in providing realistic AI chatbot interactions and customization options for your AI girl companions. Key Features: Intuitive navigation for an immersive experience. Realistic chatbot interactions. Allows customization of AI girl companions. Features advanced capabilities for generating AI girls. AI Girlfriend: Personalized AI Girlfriends for Engaging Conversations AI-Girlfriend.co is the perfect choice for those seeking personalized AI girlfriends. This platform allows you to tailor your AI girlfriend according to your preferences. AI-Girlfriend.co creates engaging and realistic interactions with your ideal AI girlfriend character. Key Features: Provides realistic AI companion interactions with varied emotions and backgrounds. Abundance of features available for diverse AI girlfriend interactions. Offers budget-friendly pricing for personalized AI girlfriends. AI Companion: Engage with AI waifus and husbands AI-Companion.co is known for its wide range of character options in the AI girl generator domain. This versatile platform accommodates various conversations and interactions with AI chatbots, offering personalized experiences. Key Features: Support for multiple languages, enhancing accessibility. Personalization options to tailor the chatbot according to individual preferences. Broad spectrum of interests and character types for diverse user needs. Frequently Asked Questions Q: What is an AI girl generator? A: An AI girl generator is a software application that uses artificial intelligence to create virtual AI girl characters for various purposes, such as entertainment, interaction, or chatbot companionship. Q: How do AI girl generators work? A: AI girl generators work by utilizing advanced algorithms and machine learning techniques to generate AI girl characters with customizable traits, personalities, and conversation capabilities. Q: Can a AI girl generator be used for NSFW content? A: Some AI generated girls are designed to cater to NSFW (Not Safe For Work) content, offering options for more mature and adult-themed interactions. However, not all AI girl generator apps support explicit content. Q: Can I customize AI girl characters generated by these tools? A: Yes, most AI girl generator apps allow users to customize AI girl characters by selecting specific traits, appearances, and personalities to create personalized virtual companions. Q: Are there age restrictions for using AI girl generators? A: Yes, to use AI girl generators, users typically need to be at least 18 years old, as these tools may generate content that is intended for adults. Conclusion In the realm of technology, AI generated girls offer a gateway to interactive virtual companionship. These tools have transformed how we connect with AI characters, providing endless entertainment and personal interactions. Whether you seek customizable AI girls, engaging AI girlfriends, or glamorous AI characters, these apps cater to diverse preferences. They bridge the virtual and real worlds, offering a glimpse into the potential of AI companions. This guide has highlighted top AI girl generator apps in 2024, each with unique features. Some may include NSFW content, so choose accordingly. AI girlfriend apps pioneer technological innovation, enabling users to create, personalize, and interact with AI characters. Explore these apps for a distinctive experience in the world of AI companionship. Unlock the potential of AI girl generators today. GPTGirlfriend.online is the most advanced AI companion subscription service with a community of more than 1,000,000 Monthly Active Users. With more than 25,000 characters, it has transformed how people interact with and experience AI. Please refer to our detailed Terms of Use and Community Guidelines for comprehensive information on usage, safety, and ethical considerations on GPTGirlfriend.online Contact Details GPTGirlfriend Business hello@enias.io Company Website https://www.gptgirlfriend.online

February 01, 2024 08:30 AM Eastern Standard Time

Image

News Release

The Medical University of Vienna's Paediatric Heart Centre Purchases Ventripoint's AI-Powered Heart Imaging System

Ventripoint Diagnostics Ltd.

Toronto, Ontario – TheNewswire – February 1, 2024 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT ); ( OTC:VPTDF), a leader in using AI for heart imaging, is pleased to announce The Paediatric Heart Centre at the Medical University of Vienna has chosen to adopt the VMS+ as its cardiac diagnostic tool. The Paediatric Cardiology Department is part of the Children’s Heart Centre Vienna and is the oldest pediatric cardiology department in Austria. The core unit is the Department of Paediatric Cardiology, located at the University Hospital for Children and Adolescent Medicine. “We are very excited to be partnering with this world-renowned hospital to bring our technology to the doctors and patients at The Paediatric Heart Centre cardiac-care programs,” said Dr. Alvira Macanovic, Ventripoint’s CEO and President. “This continues our strategy of placing our VMS+ diagnostic units, which offer a cost-effective alternative to cardiac MRIs, in leading hospitals around the world.” Using the VMS+, caregivers at the Paediatric Cardiology Department can use ultrasound images to create detailed heart scans in minutes at a fraction of the costs of MRIs. The Paediatric Cardiology Department provides world-renowned care for children with heart disease and is widely recognized for having industry leaders as its main care providers. Ventripoint is committed to improving patient care through innovative technologies like the VMS+ and will continue to bring our AI-powered diagnostic technologies to healthcare professionals and institutions. About Ventripoint Diagnostics Ltd. Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada. For further information, please contact: Jonathan Robinson CFA JRobinson@oakhillfinancial.ca (416) 669-1001 Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. Forward Looking Statements This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends'' and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

February 01, 2024 08:00 AM Eastern Standard Time

News Release

DEI in Business: Just Be Fair, Respect People and Appreciate Differences

500NewsWire

Miami, Florida, Jan. 30, 2024 - ( 500NewsWire ) -- Business owners know that the success business success is tied to employee success and retainage. At EcoVentures Capital Fund employees (and clients) come in all shapes, sizes colors, religions and orientations, and successful businesses sustain relationships for years, some for decades. Fair wages are one reason but research says that treating people fairly and respectfully regardless of personal backgrounds is essential. Miami Beach features diverse, inclusive and equitable workspaces which lead to more successful outcomes. Unfortunately, the practice of inclusivity has been hijacked by people who created policing mechanisms that have led to tolerance of hate, hate speech, and hateful acts. This cannot be allowed in schools, institutions or the workplace. This dogma, which is bad for business, must be addressed. DEI programs and policies are often used to create categories of “oppressed” and “oppressor.” However, a simplified DEI 2.0 is clearer; just don’t hate. Respect. Respect everyone. Because of the war in the Middle East Jews, an oppressed people for centuries, are labeled “oppressor” as are white people and Asians. But, all Whites, Asians and Jews are not oppressors. Twenty-five years ago Miami Beach was America’s true melting pot. All voices, colors, sizes and orientations were welcomed. America’s greatness was based on the melting pot—the drive to assimilate and follow the American Dream. Wikipedia says a melting pot is “a monocultural metaphor for a heterogeneous society becoming more homogeneous, the different elements “melting together” with a common culture.” The melting pot created a vibrant society and economy. It remains a beautiful ideal. People don’t have to be the same, but needs shared values and goals. People of all faiths, colors and genders can agree that an extreme DEI orthodoxy doesn’t work. Hate aimed at an “oppressor” is tolerated but hate aimed at those who are “oppressed” is a crime. But all hate is bad. Muslim-American CNN analyst Fareed Zakaria says about DEI “In this context it is understandable that Jewish groups wonder, why do safe spaces, microaggressions, and hate speech not apply to us?” Journalist Jonathan Tobin of the Jewish News Syndicate wrote “DEI is hostile to a diversity of opinion, opposed to equality, and inclusive only of certain approved minorities (a term interpreted as excluding Jews.)” Hedge fund activist Bill Ackman says that (DEI) sees the oppressor class including white males, Asians, Jews and other people perceived to be successful and powerful.” The labels of “oppressed” and “oppressor” limit the ability to fully grasp the human condition and the relationship between people and cultures and communities. Respecting differences and rejecting all hate, hateful acts and hate speech can help the culture move forward together. Businesses and clients are different ages and genders, different cultures and colors and faiths. For success, employees and employers must work together. Many have done so years before DEI. The well-being of employees and the well-being of business are related. Businesses don’t need DEI to tell them that treating people fairly and respectfully regardless of personal backgrounds makes business sense. PULL QUOTE Unfortunately, the practice of inclusivity has been hijacked by people who created policing mechanisms that have led to tolerance of hate, hate speech, and hateful acts. This cannot be tolerated in schools, institutions or the workplace. About George Lindemann: George Lindemann has lived in Miami Beach for 25 years. He is a father, philanthropist, conservationist, writer, businessman and Chair of The Bass Museum. Media Contact George Lindemann, President, EcoVentures Capital Fund, 1 (305) 573-1626, georgelylelindemann@gmail.com, https://www.georgelindemann.com/ SOURCE George Lindemann Contact Details George Lindemann georgelylelindemann@gmail.com Company Website https://www.georgelindemann.com/

January 30, 2024 04:00 PM Eastern Standard Time

PathAI launches six additional oncology indications for PathExplore, an AI-powered pathology panel for spatial analysis of the tumor microenvironment

PathAI

PathAI, a global leader in AI-powered pathology, today announced the launch of six additional oncology indications for PathExplore™, the world’s first structured, standardized and scalable panel for characterization of the tumor microenvironment (TME) from hematoxylin and eosin (H&E)-stained whole-slide images (WSIs). The additional indications are ovarian, bladder, liver, small cell lung, lymphoma, and head and neck cancers. PathExplore first launched in April 2023 with 8 indications, including non-small cell lung, breast, colorectal, skin, gastric, prostate, kidney, and pancreatic cancers. With this expansion, PathExplore human interpretable features (HIFs) will now be available across 14 oncology indications to accelerate the next phase of precision oncology. The last decade has seen significant strides in oncology drug development, but challenges remain – many cancer patients do not respond to available treatments, and many aren’t eligible for potentially transformative therapies because of a lack of actionable biomarkers. Distinct cell populations, tissue structures, and their spatial distributions across the TME represent some of the most promising areas of oncology research, however; traditional approaches are unable to access the full resolution of histopathology data at scale. “Pathology is the only data modality to define and quantify morphological changes resulting from treatment or disease progression,” said Andy Beck, M.D., Ph.D., chief executive officer and co-founder of PathAI. “PathExplore enables researchers and drug developers to effortlessly investigate standard characteristics of the TME, such as the abundance of tumor-infiltrating lymphocytes, as well as spatial characteristics that were previously impossible to measure such as the ratio of lymphocytes to fibroblasts near the epithelial-stromal interface.” Since launch, PathExplore has established itself as the gold-standard in AI-powered digital pathology for oncology drug development. PathAI has partnered with over 50 pharma, biotech, academic, and laboratory partners to analyze >150,000 WSIs, resulting in 50+ publications and presentations. “PathExplore represents a tremendous leap forward in biological research, bypassing long standing constraints of many existing modalities by combining the widespread availability of H&E with the unprecedented resolution of AI,” said Mike Montalto, PhD, chief scientific officer at PathAI. “By expanding the availability of PathExplore’s structured pathology data into new disease areas, we’re empowering drug developers to continue to uncover insights that go beyond existing biomarkers.” To learn more about PathExplore, download our ebook that highlights real-world applications of AI-powered pathology solutions including PathExplore, in various stages of drug development programs. PathExplore is For Research Use Only. Not for use in diagnostic procedures. About PathAI PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and laboratory use. Their AI-powered models are rigorously trained and validated with data from more than 15 million annotations and are used to optimize the analysis of pathology samples to improve efficiency and accuracy, while also accelerating drug development. PathAI is headquartered in Boston, MA, and manages a CAP/CLIA-certified laboratory in Memphis, TN. For more information, please visit www.pathai.com. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

January 30, 2024 10:00 AM Eastern Standard Time

p0 launches from stealth with $6.5m to stop catastrophic software failures using Generative AI

p0 Inc

In an increasingly competitive and malicious environment vulnerabilities in enterprise codebases can lead to catastrophic security failures. Many times these can be fatal for businesses built on a foundation of customer trust and reliability. Data security is the most fundamental promise that a business can make to its users. Despite this, we have grown accustomed to hearing about massive data exploits on an almost daily basis. It is logical that recent research has found that 71% of software engineers are concerned about software reliability at their workplace. p0 has launched from stealth and today announces that it has raised $6.5m from Lightspeed Venture Partners with participation from Alchemy Ventures to help stop catastrophic software failures. p0’s proprietary technology leverages Large Language Models (LLMs) to identify safety and security issues in software before it is ever run in a production environment. p0’s technology provides a single-click solution with no need for additional user configuration. p0 can handle a wide range of software issues including data integrity issues and validation failures (including those affecting data security), alongside speed and timeout issues. p0 noiselessly surfaces intelligent and actionable output far more effectively than traditional software reliability and security solutions. Through developer teams simply connecting their Git code repositories to p0, they can rapidly gain insight beyond what traditional rule-based static analysis tools can provide - with the ability to run code scans in just 1-click. Prakash Sanker, Co-Founder and CTO of p0 said: “Across the world, recent catastrophic software failures have led to real-world impact on human life and poor outcomes for businesses. At p0, we are determined to stop these safety and security issues affecting our society. Leveraging AI, we can go further than traditional software reliability and security tools to ensure society sees the benefits of technology with less risk.” Kunal Agarwal, Co-Founder and CEO of p0 commented: “We’re building a phenomenal team and product at p0, all focussed around protecting our clients and their users the damage that software vulnerabilities and reliability bugs can cause. “As software becomes more intricate and pervasive, the importance of robust testing and reliability checks has never been more apparent. p0 is here to fundamentally change how organisations tackle these challenges head-on by harnessing the analytical power of AI. Our innovative approach empowers developers to write safer, more secure code thereby pre-empting serious run-time failures and exploits..” Before founding p0, Sanker studied maths and computer science at Stanford University and worked at companies including Palantir. Agarwal, an economics graduate from Harvard College, has previously founded a company backed by Lightspeed, Priority Vendor Technologies, which was acquired by Kansas-based C2FO in 2019. p0 will use the capital to develop its product further, as it seeks to gain adoption from more users and build its team further. Hemant Mohapatra, Partner at Lightspeed, commented: "“At Lightspeed we’ve backed over 50 companies using generative AI to create new markets and upend old ones. p0’s cutting-edge approach to code and API security is unique and amongst the first ever truly LLM-native ways of solving this age-old and ever-evolving problem. We are excited to have incubated and backed them from when this was just an idea on paper” About p0 Founded by Prakash Sanker and Kunal Agarwal, p0 leverages AI to help software teams surface critical security issues in software before their code is deployed to production. Through connecting with Git code repositories, p0 can identify a variety of software issues, using Generative AI to go further in identifying bugs than other tools can. For more information, please visit https://p0.inc/ About Lightspeed Lightspeed is a global multi-stage venture capital firm focused on accelerating disruptive innovations and trends in the Enterprise, Consumer, and Health sectors. Since 2000, Lightspeed has backed entrepreneurs and helped build companies of tomorrow, including: Affirm, Acceldata, AppDynamics, Darwinbox, Hasura, Nutanix, OYO, Razorpay, Snap, Supabase, and Udaan. Lightspeed and its affiliates currently manage more than $18 Billion across the global Lightspeed platform, with investment professionals and advisors in India, Silicon Valley, Israel, China, Southeast Asia and Europe. www.lsip.com Contact Details p0 Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://p0.inc/

January 30, 2024 09:00 AM Eastern Standard Time

Image

American Medical Association Grants Cardio Diagnostics (NASDAQ: CDIO) Reimbursement Codes For AI-Powered Coronary Heart Disease Tests

Cardio Diagnostics Holdings, Inc

By Jeremy Golden, Benzinga Cardio Diagnostics’ AI-driven coronary heart disease (CHD) tests have taken another promising step in their evolution. Cardio Diagnostics (NASDAQ: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, has been assigned two dedicated Current Procedural Terminology (CPT) Proprietary Laboratory Analysis (PLA); 0440U for the company’s AI-driven CHD detection test, PrecisionCHD, and 0439U for the company’s AI-driven CHD event (heart attack) risk assessment test, Epi+Gen CHD. Assigned by the American Medical Association (AMA), these two new CPT PLA codes – effective April 1, 2024 – mark a significant step toward payer billing and payment for the company’s groundbreaking tests. The designation will facilitate the broader adoption of PrecisionCHD, an integrated genetic-epigenetic clinical blood test to aid in the diagnosis of CHD, and Epi+Gen CHD for evaluating the likelihood of a patient experiencing a CHD event – mainly a heart attack – within the next three years. Treating A Growing Problem Every year, about 805,000 people in the United States have a heart attack, meaning someone experiences a heart attack every 40 seconds. Heart disease is the leading cause of death for both men and women. According to the CDC, in 2021, heart disease was responsible for the deaths of more than 695,000 Americans – representing one in every five deaths. The most common type of heart disease and the major cause of heart attacks, CHD was responsible for over 375,000 deaths in 2021, and CHD-associated medical costs are estimated to be about $239.9 billion according to an estimate by the CDC in its heart disease fact sheet. Combating this growing problem, Cardio Diagnostics reports that PrecisionCHD is the first integrated genetic-epigenetic test for the detection of CHD. The PrecisionCHD test has the ability to aid in the diagnosis of CHD and provide personalized insights to help prevent a heart attack and improve outcomes. With the introduction of PrecisionCHD, clinicians are armed with a powerful, scalable and non-invasive alternative that comes in the form of a blood-based test that uses artificial intelligence, along with personalized genetic and epigenetic information, to sensitively detect the presence of CHD. Identifying patients with CHD and intervening before a heart attack occurs are essential to reducing the unprecedented economic and health burden associated with CHD. Until now, the lack of readily accessible and cost-effective diagnostic solutions for CHD has posed a challenge leading to delayed diagnosis and care, particularly among underserved and minority populations. Increasing access, the PrecisionCHD test only requires a simple blood draw and can be deployed remotely, allowing it to be scaled without the need for specialized infrastructure. This enables more timely intervention and management. “Receiving a dedicated CPT PLA code for PrecisionCHD is a critical milestone in our commercialization strategy,” said Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics. “With PrecisionCHD, we believe that expanding equitable access to CHD diagnostics and improving patient health outcomes while reducing healthcare expenditure is possible.” While PrecisionCHD aids in diagnosing CHD, Cardio Diagnostics’ Epi+Gen CHD evaluates an individual’s genetic and epigenetics to predict their risk for a heart attack or sudden cardiac death associated with CHD. By leveraging the powerful personalized insights driven by the company’s groundbreaking epigenetic-genetic technology, the company can provide patient-specific epigenetic and genetic drivers of CHD to help guide preventive care that could potentially save lives. In peer-reviewed studies, Epi+Gen CHD was more cost-effective and sensitive for assessing heart attack risk when compared to standard lipid-based risk calculators. Specifically, in a validation study conducted with Intermountain Healthcare, Epi+Gen CHD was shown to be, on average, about twice as sensitive in detecting risk for a CHD event in women than lipid-based calculators. For employers, the financial burden of heart attacks includes direct costs related to diagnosing, managing and treating heart disease. Indirect costs include lost productivity due to employee absenteeism and short-term disability, which can indirectly cost employers about $1,119 per month for upwards of three years. Cardio Diagnostics’ technology can help employers better inform their benefits offerings by combining the ability to offer employees the advanced Epi+Gen CHD heart attack risk test with aggregated risk data. Cardio Diagnostics’ Employer Risk Intelligence platform provides employers and brokers with the first-of-its-kind cardiovascular employee population health intelligence backed by a clinical test and layered insights, completed in a compliant manner. As such, Epi+Gen CHD’s new reimbursement code could mean greater access to technology that enables a healthier workforce and significant savings in healthcare costs related to heart disease. “Cardio Diagnostics is committed to driving widespread adoption of our solutions, and obtaining a reimbursement code for Epi+Gen CHD is a critical milestone in our commercialization strategy and for gaining reimbursement from federal and private payers,” Dogan said. Cardio Diagnostics continues to lead the way in precision cardiovascular medicine, leveraging the power of AI and epigenetics to help prevent heart attacks. The company is committed to making heart disease risk assessment, detection and management more accessible, and it believes personalized and precise diagnostics are key to winning the fight against the leading cause of death in the United States. Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit www.cardiodiagnosticsinc.com. Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," “goal,” or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, regulatory matters, protection of technology, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Current Report on Form 10-K for the period ended December 31, 2022 and Form 10-Q for the period ended March 31, 2023, under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Gene Mannheimer - Investor Relations +1 855-226-9991 investors@cardiodiagnosticsinc.com Company Website https://cardiodiagnosticsinc.com/

January 30, 2024 08:20 AM Eastern Standard Time

1 ... 55 56 57 58 59 ... 310

Back